TwinStrand Biosciences
Clonal Expansion Limited in Stem Cell Transplant Recipients, Even After Long Time
Researchers used ultra-sensitive duplex sequencing to compare clonal hematopoiesis and myeloid cancer-related mutation patterns in transplant donors and recipients over time.
Top Five Articles on GenomeWeb Last Week: Guardant Health $83.4M Lawsuit Verdict, More
Last week, GenomeWeb's readers were most interested in news that Guardant Health is liable for $83.4 million in damages in an intellectual property legal battle with TwinStrand Biosciences.
Jury Levies $83.4M Verdict Against Guardant Health in TwinStrand Biosciences Patent Lawsuit
Guardant said that it plans to appeal the decision made by a jury in the US District Court for the District of Delaware.
The UK-based firm is exploring several applications in cancer, including diagnostics, as well as genotoxicity testing in the environmental space.
People in the News at MPI for Evolutionary Anthropology, Roche, TwinStrand, Quantum-Si, More
Executive appointments, promotions, and departures in omics and molecular diagnostics for the week of Oct. 3, 2022.